DAIC

JULY 10, 2024

“This latest patent further secures the broad therapeutic potential of brilaroxazine for inflammatory conditions driven by underlying disruption in serotonin signaling like pulmonary hypertension,” said Laxminarayan Bhat, Ph.D. Founder, President, and CEO. Brilaroxazine has already received Orphan Drug Designation by the U.S.

Pulmonary 111

Pulmonary Hypertension Pharmacology Biomarkers 111

DAIC

FEBRUARY 27, 2024

milla1cf Tue, 02/27/2024 - 17:29 February 27, 2024 — Aria CV, Inc , a developer of medical devices treating pulmonary hypertension, today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St.

Pulmonary 110

Pulmonary Hypertension Heart Failure Blood Pressure 110

Journal of Cardiothoracic Surgery

AUGUST 20, 2024

This research evaluates the effect of balloon pulmonary angioplasty (BPA) on cardiac electrophysiological changes in patients with chronic thromboembolic pulmonary hypertension (CTEPH).

Angioplasty 52

Angioplasty Pulmonary Hypertension Electrophysiology 52

Frontiers in Cardiovascular Medicine

JULY 24, 2024

Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a severe and complex condition that evolves from unresolved pulmonary embolism, leading to fibrotic obstruction of pulmonary arteries, pulmonary hypertension, and potential right heart failure.

Pulmonary 52

Pulmonary Hypertension Angioplasty Pharmacology 52

Heart BMJ

AUGUST 26, 2024

Chronic thromboembolic pulmonary hypertension (CTEPH) is a complex pulmonary vascular disorder that involves major vessel and microvascular disease components. Fibrotic obstructions resulting from unresolved pulmonary emboli constitute the major vessel disease component.

Pulmonary 52

Pulmonary Hypertension Biomarkers Angioplasty 52

Journal of Clinical Investigation - Cardiology

FEBRUARY 1, 2024

Pulmonary arterial hypertension (PAH) is a devastating and progressive disease with limited treatment options. Endothelial haploinsufficiency of RAB7 caused spontaneous pulmonary hypertension (PH) in mice. Here, we explored the role of RAB7 in endothelial cell (EC) function and lung vascular homeostasis.

Pulmonary 98

Pulmonary Hypertension 98

DAIC

DECEMBER 13, 2023

Pulmonary arterial hypertension, a form of high blood pressure that occurs in the lungs, is a target of research by Cedars-Sinai investigators. Pulmonary arterial hypertension is a rare disease, affecting fewer than 100 people per million. Siegel Family Foundation Distinguished Professor and senior author of the study. “We

Pulmonary 105

Pulmonary Hypertension Blood Pressure Research 105

Medical Xpress - Cardiology

JULY 8, 2024

Pulmonary hypertension is a very serious disease that leads to heart failure and death in many patients.

Pulmonary 88

Pulmonary Hypertension Physiology Heart Failure 88

Medical Xpress - Cardiology

MAY 2, 2024

This difference becomes clear in pulmonary hypertension, in which only the lungs' blood vessels stiffen progressively, leading to chronic lung disease, heart failure and death. Blood vessels in the lungs aren't like the others in the body.

Pulmonary 75

Pulmonary Hypertension Heart Failure 75

American College of Cardiology

AUGUST 7, 2024

In this week’s View, Dr. Eagle looks at post-capillary pulmonary hypertension in heart failure and the revised European guideline definition. He then explores obesity in adolescents and its impact on our societal health.

Obesity 61

Obesity Pulmonary Hypertension TAVR 61

American College of Cardiology

JUNE 10, 2024

What is the comparative effectiveness of therapies targeting the different treatment pathways in pulmonary arterial hypertension (PAH)?

Pulmonary 53

Pulmonary Hypertension Article 53

All About Cardiovascular System and Disorders

APRIL 7, 2024

Transcript of the video: Now we will discuss a chest X-ray showing antler sign in pulmonary venous hypertension. So, the shape of the upper lobe vessels in venous hypertension, pulmonary venous hypertension, will be resembling the antlers of the stag. You can see the antlers here.

Pulmonary 52

Pulmonary Hypertension General Cardiology 52

Medical Xpress - Cardiology

MARCH 29, 2024

Food and Drug Administration has approved Winrevair (sotatercept-csrk) as an injectable treatment for pulmonary arterial hypertension (PAH) in adults.

Pulmonary 77

Pulmonary Hypertension 77

Science Daily - Heart Disease

DECEMBER 13, 2023

Infusions of potentially therapeutic cells derived from the heart are safe for people with pulmonary arterial hypertension, a form of high blood pressure that occurs in the blood vessels of the lungs and typically affects middle-aged women, according to a new study.

Pulmonary 97

Pulmonary Hypertension Blood Pressure 97

The British Journal of Cardiology

JANUARY 16, 2024

Pulmonary hypertension is a rare disease, associated with a significant deterioration in quality of life, usually not curable and with an ominous prognosis. We present the case of a patient diagnosed with precapillary component pulmonary hypertension, with the finding of an arteriovenous fistula at the peripheral level.

Pulmonary 52

Pulmonary Hypertension Quality of Life Article 52

American College of Cardiology

JUNE 28, 2024

For the treatment of pulmonary arterial hypertension (PAH), is sildenafil 80 mg TID noninferior to sildenafil 5 mg TID for all-cause mortality?

Pulmonary 58

Pulmonary Hypertension Article 58

DAIC

MAY 6, 2024

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

Open Heart

MAY 7, 2024

Background The treatment of pulmonary hypertension (PH) has improved rapidly in recent decades. Treatment escalation was defined as an additional pulmonary arterial hypertension (PAH) drug, pulmonary endarterectomy, percutaneous balloon angioplasty or bilateral lung transplantation.

Heart Monitor 52

Heart Monitor Pulmonary Hypertension Angioplasty 52

Medical Xpress - Cardiology

JANUARY 19, 2024

A research team has discovered a possible therapeutic target for pulmonary hypertension.

Pulmonary 101

Pulmonary Hypertension Cardiac Function Research 101

Medical Xpress - Cardiology

DECEMBER 13, 2023

Infusions of potentially therapeutic cells derived from the heart are safe for people with pulmonary arterial hypertension, a form of high blood pressure that occurs in the blood vessels of the lungs and typically affects middle-aged women, according to a study led by Cedars-Sinai investigators.

Pulmonary 85

Pulmonary Hypertension Blood Pressure 85

American College of Cardiology

JUNE 12, 2024

In this week’s View, Dr. Eagle looks at excess apolipoprotein-B and cardiovascular risk, then examines a recent meta-analysis on treating pulmonary arterial hypertension.

Pulmonary 58

Pulmonary Hypertension Outcomes Article 58

Med Page Today

DECEMBER 12, 2023

(MedPage Today) -- Stable patients with pulmonary vascular disease (PVD) tolerated travel to high altitudes fairly well with frequent monitoring and supplemental oxygen therapy provided as necessary, a field study found. Despite the perceived.

Pulmonary 105

Pulmonary Hypertension 105

American College of Cardiology

DECEMBER 14, 2023

What is the impact on prognosis of the 2022 ESC/ERS pulmonary hypertension (PH) guidelines on the new redefined hemodynamic threshold for the diagnosis of precapillary PH?

Pulmonary 49

Pulmonary Hypertension Outcomes Article 49

Frontiers in Cardiovascular Medicine

MAY 8, 2024

Patients with pulmonary hypertension associated with a left-right shunt include a wide spectrum of pathophysiological substrates, ranging from those characterized by pulmonary over-circulation to those with advanced pulmonary vascular disease.

Congenital Heart Disease 52

Congenital Heart Disease Pulmonary Hypertension Congenital 52

Circulation

MARCH 7, 2024

Balloon pulmonary angioplasty continues to gain traction as a treatment option for patients with chronic thromboembolic pulmonary disease with and without pulmonary hypertension. Not surprisingly, chronic thromboembolic pulmonary hypertension centers are rapidly initiating balloon pulmonary angioplasty programs.

Angioplasty 45

Angioplasty Pulmonary Hypertension Document 45

American College of Cardiology

JANUARY 23, 2024

The goal of the A DUE trial was to compare the safety and efficacy of macitentan/tadalafil combination therapy versus macitentan and tadalafil monotherapies in patients with pulmonary arterial hypertension (PAH).

Pulmonary 53

Pulmonary Hypertension Article 53

Heart BMJ

AUGUST 26, 2024

Background Decreased diffusing capacity of the lungs for carbon monoxide (DLco) is associated with microvascular damage in chronic thromboembolic pulmonary hypertension (CTEPH). However, low DLco may attenuate the effect of BPA on mPAP and pulmonary vascular resistance and require more treatment sessions. mm Hg) before BPA.

Angioplasty 52

Angioplasty Pulmonary Exercise Hypertension 52

Frontiers in Cardiovascular Medicine

JULY 24, 2024

BackgroundThe relationship between human immunodeficiency virus (HIV) infection and pulmonary arterial hypertension (PAH) has garnered significant scrutiny. Individuals with HIV infection have a higher risk of developing PAH. However, the specific mechanism of HIV-associated PAH remains unclear.

Pulmonary 52

Pulmonary Hypertension Biomarkers Download 52

All About Cardiovascular System and Disorders

FEBRUARY 2, 2024

Biatrial enlargement with pulmonary venous hypertension

Pulmonary 52

Pulmonary Hypertension General Cardiology 52

Circulation

JANUARY 12, 2024

BACKGROUND:Pulmonary hypertension, characterized by vascular remodeling, currently lacks curative therapeutic options. The dysfunction of pulmonary artery endothelial cells plays a pivotal role in the initiation and progression of pulmonary hypertension (PH). Circulation, Ahead of Print.

Pulmonary 45

Pulmonary Hypertension Biomarkers Circulation 45

Frontiers in Cardiovascular Medicine

JANUARY 2, 2024

If pulmonary hypertension is additionally involved with vasoplegic syndrome, circulation management becomes much more complicated. The aim of this study is to investigate whether pituitrin is beneficial for the postoperative outcomes in patients with pulmonary hypertension undergoing cardiac surgery.

Pulmonary 59

Pulmonary Hypertension Outcomes Circulation 59

Frontiers in Cardiovascular Medicine

FEBRUARY 11, 2024

Background Pulmonary arterial hypertension (PAH) is a severe and rare disease in the cardiopulmonary system. Its pathogenesis involves vascular remodeling of the pulmonary artery, which results in progressive increases in pulmonary arterial pressure.

Pulmonary 59

Pulmonary Hypertension Heart Failure 59

Heart BMJ

MAY 10, 2024

Objectives The association of pulmonary hypertension (PH) with the outcome after mitral transcatheter edge-to-edge repair (M-TEER) focusing on the new ESC/ERS guidelines definition for PH. Background PH is frequently found in patients with mitral regurgitation and is associated with lower survival rates. p<0.001).

Bicuspid/Mitral 52

Bicuspid/Mitral Pulmonary Hypertension Outcomes 52

Heart BMJ

MARCH 22, 2024

Challenges in the diagnosis of pulmonary hypertension Pulmonary hypertension (PH) is a clinical–physiological syndrome thought to affect 1% of the global population. 1 PH is defined haemodynamically by mean pulmonary artery pressure >20 mm Hg, resulting in right ventricular (RV) overload and often RV failure.

Pulmonary 40

Pulmonary Hypertension Physiology 40

Journal of Cardiovascular Pharmacology

JULY 1, 2024

However, whether AMOTL2 is linked to pulmonary arterial hypertension (PAH) has not been addressed. Overexpression of AMOTL2 also led to a noteworthy decrease in vascular wall thickness, pulmonary artery area, and collagen deposition in rats with PAH. This work aimed to investigate the potential role of AMOTL2 in PAH.

Pulmonary 40

Pulmonary Hypertension Physiology Article 40

HeartRhythm

APRIL 30, 2024

Background: Patients with atrial fibrillation (AF) and concomitant pulmonary hypertension (pHTN) have an increased risk of morbidity and mortality. However, the outcomes of catheter ablation in this cohort are unclear.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Hypertension Ablation 40

Heart BMJ

FEBRUARY 12, 2024

Pulmonary arterial hypertension related to congenital heart disease as a paradigm of complexity Pulmonary arterial hypertension related to congenital heart disease (PAH-CHD) really represents a paradigm of complexity.

Congenital Heart Disease 40

Congenital Heart Disease Congenital Pulmonary Heart Disease 40